Clinical trials: Sildenafil
Pulmonary Arterial Hypertension
Combination Therapy in Pulmonary Arterial Hypertension
An open label, non-comparative study design is appropriate for this Phase 4 study designed to assess whether a core therapy of bosentan, either as monotherapy or with the addition of sildenafil, enables patients with pulmonary…
- Trial name
- COMPASS 3 (NCT00433329)
- Testing
- Bosentan, Sildenafil
- Volunteers
- 100 people
- Sponsor
- Actelion
Thalassemia
L-arginine Versus Sildenafil in Children With Beta Thalassemia Associated With Pulmonary Hypertension
This study compares L-arginine Versus Sildenafil as treatment for pulmonary hypertension in Children with Beta Thalassemia
- Trial name
- NCT03402191
- Testing
- L-arginine, Sildenafil
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sherief Abd-Elsalam
Neonates and Preterm Infants
PK Study of Sildenafil in Neonate
The purpose of this study is to investigate the pharmacokinetics of sildenafil which is used as treatment of pulmonary hypertension in neonate and preterm infant.
- Trial name
- NCT02244528
- Testing
- Sildenafil
- Where
- 2 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Persistent Pulmonary Hypertension of the Newborn
Pharmacokinetics of Sildenafil in Premature Infants
The purpose of this study is to learn more about the safety and dosing of sildenafil in infants.
- Trial name
- NCT01670136
- Testing
- 1 dose of sildenafil
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of North Carolina, Chapel Hill
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)
COMPERA / COMPERA-KIDS
In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only provide part of the information needed for…
- Trial name
- COMPERA (NCT01347216)
- Where
- 7 sites in Belgium, Germany and 2 more
- Volunteers
- 14,000 people
- Sponsor
- Technische Universität Dresden
Congenital Disorders
Pulmonary Hypertension in Trisomy 21 Patients
Evidence has shown poor outcome for adult patients with pre-operative pulmonary hypertension following closure of an atrial septal defect.
- Trial name
- NCT00478296
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Healthcare of Atlanta
Pediatric Pulmonary Hypertension
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better…
- Trial name
- MoD (NCT04039464)
- Testing
- Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Johns Hopkins University
Hypoplastic Left Heart Syndrome, Tricuspid Atresia
Sildenafil After the Fontan Operation
In this study, the investigators will evaluate the effect of sildenafil on exercise tolerance in patients with a single cardiac ventricle who have undergone the Fontan operation.
- Trial name
- SAFO (NCT00507819)
- Testing
- Sildenafil
- Volunteers
- 28 people
- Sponsor
- Children's Hospital of Philadelphia
Alopecia Areata
A Novel Formulation of Sildenafil-loaded Nanocarriers for Treatment of Alopecia Areata
Alopecia areata (AA) is a common cause of nonscarring alopecia that occurs in a patchy, confluent, or diffuse pattern. Many theories were implicated in pathogenesis of AA, such as an autoimmune lymphocytic attack of the hair…
- Trial name
- NCT06527729
- Testing
- sildenafil-loaded liposomes, minoxidil gel
- Where
- Egypt
- Volunteers
- 28 people
- Sponsor
- Assiut University
PPHN
Vardenafil Vs Sildenafil for the Treatment of Pulmonary Hypertension of the Newborn
The goal of this clinical trial is to learn if drug Vardenafil works to treat pulmonary hypertension in newborns, It will also learn about the safety of Vardenafil.
- Trial name
- PPHN (NCT06860399)
- Testing
- Vardenafil, Sildenafil
- Where
- Syria
- Volunteers
- 55 people
- Sponsor
- Damascus University
Pulmonary Arterial Hypertension
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
- Trial name
- Aspire (NCT01266265)
- Testing
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin
- Where
- 88 sites in United States
- Volunteers
- 1,333 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension (PAH)
Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients
Eisenmenger's syndrome presents as a severe clinical picture of polymorbidity that constitutes a great burden at the individual as well as the familial and social level.
- Trial name
- NCT00586794
- Testing
- Sildenafil
- Where
- 20 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Competence Network for Congenital Heart Defects
Pulmonary Arterial Hypertension
An Open Label Access Study For Subjects Who Completed A1481156
The purpose of this study is to provide sildenafil therapy to subjects who have completed the A1481156 study for the treatment of Pulmonary Arterial Hypertension (PAH) in India and are judged by the Investigator to derive…
- Trial name
- NCT01582438
- Testing
- Access program - sildenafil citrate, Viagra, Revatio
- Where
- India
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
As monotherapy for pulmonary arterial hypertension (PAH) begins to fail additional therapies are introduced. Although co-administration of sitaxsentan and sildenafil is well tolerated the controlled safety/efficacy database of…
- Trial name
- NCT00796666
- Testing
- Sitaxsentan, Sitaxsentan and Sildenafil
- Where
- 48 sites in United States, Argentina and 16 more
- Volunteers
- 131 people
- Sponsor
- Pfizer
Lymphangioma
A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations
There is an unsatisfied medical need for a first-line treatment of lymphatic malformations with a good benefit/risk profile. Based on a patient experience in the institution, the investigators plan to verify whether or not the…
- Trial name
- NCT01290484
- Testing
- Sildenafil
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Stanford University
Liver Fibrosis
Sildenafil for Liver Fibrosis in Adolescents and Adults After Fontan Operation
Fontan operation is currently the most common procedure performed in patients with single-ventricle physiology. This surgery allows for passive caval blood flow to the pulmonary arteries in the absence of a subpulmonary pump and…
- Trial name
- NCT04908657
- Testing
- Sildenafil 20 MG
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Sickle Cell Disease, Pulmonary Hypertension
Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease
This study will examine whether the drug sildenafil can lower blood pressure in the pulmonary artery (the blood vessel that leads from the heart to the lungs) in patients with sickle cell disease and pulmonary hypertension (high…
- Trial name
- NCT00492531
- Testing
- Sildenafil
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 74 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH)…
- Trial name
- NCT00796510
- Testing
- Sitaxsentan, Sitaxsentan and Sildenafil
- Where
- 3 sites in United States, Romania and 1 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting.
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
- Trial name
- NCT00625079
- Testing
- sildenafil
- Where
- United States
- Sponsor
- University of California, Los Angeles
Persistent Pulmonary Hypertension of Newborn
Nitro Oxide Inhalation Continued With Sildenafil on Neonatal Persistent Pulmonary Hypertension
Nitro Oxide (NO) inhalation was recognized as an effect treatment of Neonatal Persistent Pulmonary Hypertension (PPHN), while the safety of NO long term application was under investigation.
- Trial name
- NCT01373749
- Testing
- NO inhalation, NO inhalation continued with sildenafil
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Third Military Medical University